Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Hrvoje Lalic"'
Autor:
Tomislav Smoljo, Barbara Tomic, Hrvoje Lalic, Vilma Dembitz, Josip Batinic, Antonio Bedalov, Dora Visnjic
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Low-dose cytarabine (LDAC) is a standard therapy for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. While high doses of cytarabine induce cytotoxicity, the precise mechanism of action of LDAC in AML remains elusive. I
Externí odkaz:
https://doaj.org/article/4b7c7824b49a4991984dc55e0d77bb7d
Autor:
Barbara Tomic, Tomislav Smoljo, Hrvoje Lalic, Vilma Dembitz, Josip Batinic, Drago Batinic, Antonio Bedalov, Dora Visnjic
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-16 (2022)
Abstract Acute myeloid leukemia (AML) is characterized by arrested differentiation making differentiation therapy a promising treatment strategy. Recent success of inhibitors of mutated isocitrate dehydrogenase (IDH) invigorated interest in different
Externí odkaz:
https://doaj.org/article/45d9eadd75b24f639201cd762383fd60
Autor:
Vilma Dembitz, Hrvoje Lalic, Ivan Kodvanj, Barbara Tomic, Josip Batinic, Klara Dubravcic, Drago Batinic, Antonio Bedalov, Dora Visnjic
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background All-trans retinoic acid (ATRA)-based treatment of acute promyelocytic leukemia (APL) is the most successful pharmacological treatment of acute myeloid leukemia (AML). Recent development of inhibitors of mutated isocitrate dehydrog
Externí odkaz:
https://doaj.org/article/b5450c27c8c44dd085ad2282cd1c406e
Publikováno v:
Oncology reports. 47(6)
Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogues, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0bf557a04d907abff238ce90d294bac
https://pubmed.ncbi.nlm.nih.gov/35506458
https://pubmed.ncbi.nlm.nih.gov/35506458
Publikováno v:
Cells
Cells, Vol 10, Iss 1095, p 1095 (2021)
Cells, Vol 10, Iss 1095, p 1095 (2021)
5-Aminoimidazole-4-carboxamide ribonucleoside (AICAr) has been one of the most commonly used pharmacological modulators of AMPK activity. The majority of early studies on the role of AMPK, both in the physiological regulation of metabolism and in can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaaf70488006988fb844a4a694beb3de
https://doi.org/10.3390/cells10051095
https://doi.org/10.3390/cells10051095
Autor:
Vilma, Dembitz, Hrvoje, Lalic, Barbara, Tomic, Tomislav, Smoljo, Josip, Batinic, Klara, Dubravcic, Drago, Batinic, Antonio, Bedalov, Dora, Visnjic
Publikováno v:
International journal of hematology. 115(1)
All-trans retinoic acid (ATRA)-based therapy for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), is the most successful example of differentiation therapy. Although ATRA can induce differentiation in some non-APL AML ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cff5f2bc5da302a2d1ebf6e24737dab2
https://pubmed.ncbi.nlm.nih.gov/34546543
https://pubmed.ncbi.nlm.nih.gov/34546543
Autor:
Magdalena Krbot Skorić, Barbara Barun, Mario Habek, Drago Batinić, Tereza Gabelić, Ivan Adamec, Antonija Babić, Hrvoje Lalic
Publikováno v:
Multiple Sclerosis and Related Disorders
Objective To evaluate clinical and laboratory effects of delaying ocrelizumab infusions during the COVID-19 pandemics in people with multiple sclerosis (pwMS). Methods We have retrospectively searched our electronic database and identified 33 pwMS wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3ebecc1286deacc13e7f14ac146499
https://doi.org/10.1016/j.msard.2020.102704
https://doi.org/10.1016/j.msard.2020.102704
Autor:
Josip Batinić, Tomislav Smoljo, Vilma Dembitz, Hrvoje Lalic, Klara Dubravčić, Antonio Bedalov, Barbara Tomic, Dora Višnjić, Drago Batinić
All-trans retinoic acid (ATRA)-based therapy for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), is the most successful example of differentiation therapy. Although ATRA can induce differentiation in some non-APL AML ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94738c0c7f83c0593dd24cbfa12a7a15
https://www.bib.irb.hr/1163615
https://www.bib.irb.hr/1163615
Autor:
Ivan Kodvanj, Hrvoje Lalic, Klara Dubravčić, Antonio Bedalov, Barbara Tomic, Dora Višnjić, Vilma Dembitz, Josip Batinić, Drago Batinić
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Background All-trans retinoic acid (ATRA)-based treatment of acute promyelocytic leukemia (APL) is the most successful pharmacological treatment of acute myeloid leukemia (AML). Recent development of inhibitors of mutated isocitrate dehydrogenase and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27b94f17d5d51c57a3edb7dde7a3530a
https://pubmed.ncbi.nlm.nih.gov/33176741
https://pubmed.ncbi.nlm.nih.gov/33176741
Publikováno v:
International Journal of Hematology. 102:12-24
Arsenic trioxide (ATO) has potent clinical activity in the treatment of patients with acute promyelocytic leukemia (APL), but is much less efficacious in acute myeloid leukemia (AML) lacking t(15;17) translocation. Recent studies have indicated that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0427ae7f54f8a600bc1704e67e6daac3
https://doi.org/10.1007/s12185-015-1776-2
https://doi.org/10.1007/s12185-015-1776-2